{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'The investigators and site staff should remain vigilant for the possible development of', 'pneumonia in patients with COPD as the clinical features of such infections overlap with', 'the symptoms of COPD exacerbations. For all suspected cases of pneumonia,', 'investigators are strongly encouraged to confirm the diagnosis (this includes obtaining a', 'chest x-ray) and to initiate appropriate therapy as promptly as possible.', 'Please refer to SPM for details on what should be considered for pneumonia', 'confirmation.', '6.4.3.5.', 'Confirm AECOPD and record start date', 'The investigator should confirm the AECOPD based on his/her medical judgement. The', 'date of onset of AECOPD will be determined as detailed in Section 3.1.1.1 and will be', 'documented in the eCRF.', '6.4.3.6.', 'Record current medication for AECOPD', 'At each study visit/contact, the investigator should question the subject about any', 'medications administered for treatment of AECOPD.', 'All medications administered for treatment of AECOPD will be recorded in the', 'eCRF.', '6.4.3.7.', 'Record healthcare resource utilisation', \"Healthcare use will be obtained through review of the subject's medical record (aided by\", 'subject self-reporting). Healthcare utilisation includes all unscheduled visits to a', 'physician office, visits to urgent care, visits to emergency department, and', 'hospitalizations. Healthcare use should be recorded in the eDiary Card and reported in the', 'eCRF at study visit. Refer to the SPM for more details and guidance on recording of', 'healthcare use.', '6.4.3.8.', 'Additional COPD treatments prescribed by primary and secondary care', 'physician', 'All treatments prescribed by the primary and secondary healthcare physician will be', 'recorded in the eCRF.', '6.4.3.9.', 'Sputum sampling (Amended 19 October 2018)', 'Sputum samples during AECOPD should preferably be obtained before', 'administration of the first dose of antibiotics to treat the AECOPD (if applicable).', 'Sputum can be collected spontaneously or can be induced, as per investigator', 'judgement. Sputum sampling should only be done if, in the opinion of the', 'investigator, it is safe for the subject.', '19-OCT-2018', '52', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', \"Sputum sample collected at subject's home (spontaneous): Self-collection of the\", 'sputum sample will be allowed in specific cases, where the first dose of antibiotics', 'absolutely needs to be taken before an AECOPD visit can take place. This is not', 'allowed at scheduled visits when subject should be in stable condition.', 'Collected sputum will be diluted in DTT, processed and cultured within 6hrs of', 'collection for microbiology testing.', 'Remaining DTT-sputum will be aliquoted as such. These samples will be kept at', '-70/80\u00b0C until shipment to GSK or GSK designated lab for testing.', 'Refer to the SPM and the Central Laboratory Investigator Manual for more details and', 'guidance on handling of sputum samples.', '6.4.3.10. HRQOL questionnaires', 'The subject will be asked to complete the HRQOL questionnaire (CAT only) by', 'himself/herself directly in the electronic Diary Card, during the AECOPD visit as', 'detailed in Table 5.', 'Refer to the SPM for more details and guidance on the HRQOL questionnaires.', '6.4.3.11. Record AECOPD severity and AECOPD end date', 'The severity and end date of each confirmed AECOPD will be recorded in the eCRF. The', 'AECOPD severity will be assessed using the AECOPD severity scale (refer Table 2) and', 'the AECOPD end date will be determined as detailed in Section 3.1.1.1 and Section', '3.1.1.2.', '6.4.3.12. Recording of AE/SAEs', 'Refer to Section 7.2 for procedures for the investigator to record AE/SAEs. Refer to', 'Section 7.3 for guidelines on how to submit SAE reports to GSK Biologicals.', 'The subjects will be instructed to contact the investigator immediately should they', 'manifest any signs or symptoms they perceive as serious.', '6.4.4.', 'Sampling', '6.4.4.1.', 'Sputum Sampling', 'Sputum sampling: Refer to section 6.4 for description of the sampling procedure.', 'Full details for obtaining sputum samples are provided in the Module on Biospecimen', 'Management in the SPM and in the Central Laboratory Investigator Manual', 'accompanying this protocol.', '19-OCT-2018', '53', '75661ebdab2e949f7a1f1bc2071b9dec72acecct']\n\n###\n\n", "completion": "END"}